KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Short-term Investments (2016 - 2025)

Astrazeneca (AZN) has 1 years of Short-term Investments data on record, last reported at $54.0 million in Q4 2024.

  • For Q4 2024, Short-term Investments changed N/A year-over-year to $54.0 million; the TTM value through Dec 2024 reached $54.0 million, changed N/A, while the annual FY2024 figure was $54.0 million, N/A changed from the prior year.
  • Short-term Investments reached $54.0 million in Q4 2024 per AZN's latest filing.
  • Across five years, Short-term Investments topped out at $54.0 million in Q4 2024 and bottomed at $54.0 million in Q4 2024.